Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Kidney Transplantation | 11 | 2021 | 5397 | 1.44 | Why? |
| Cytomegalovirus Infections | 6 | 2019 | 667 | 1.35 | Why? |
| Catheter-Related Infections | 3 | 2019 | 381 | 1.24 | Why? |
| Transplant Recipients | 13 | 2021 | 4982 | 1.12 | Why? |
| Organ Transplantation | 8 | 2021 | 2616 | 1.05 | Why? |
| Staphylococcal Infections | 4 | 2019 | 1099 | 0.90 | Why? |
| Bacteremia | 4 | 2019 | 1372 | 0.81 | Why? |
| Antifungal Agents | 6 | 2020 | 1828 | 0.75 | Why? |
| Budesonide | 1 | 2021 | 192 | 0.75 | Why? |
| Staphylococcus | 1 | 2019 | 77 | 0.74 | Why? |
| Complement C4 | 1 | 2018 | 86 | 0.70 | Why? |
| Ki-1 Antigen | 1 | 2017 | 25 | 0.69 | Why? |
| Hepcidins | 1 | 2018 | 97 | 0.68 | Why? |
| Ganciclovir | 1 | 2017 | 97 | 0.67 | Why? |
| Device Removal | 2 | 2019 | 221 | 0.67 | Why? |
| Leishmaniasis, Visceral | 1 | 2017 | 85 | 0.63 | Why? |
| Iron Overload | 1 | 2018 | 113 | 0.62 | Why? |
| Triazoles | 2 | 2020 | 440 | 0.58 | Why? |
| Immunomodulation | 2 | 2021 | 1472 | 0.58 | Why? |
| Complement C3 | 1 | 2018 | 271 | 0.58 | Why? |
| Aspergillosis | 1 | 2018 | 264 | 0.57 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.56 | Why? |
| Nitriles | 2 | 2020 | 1053 | 0.55 | Why? |
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 9335 | 0.53 | Why? |
| Biological Therapy | 1 | 2018 | 456 | 0.53 | Why? |
| Opportunistic Infections | 2 | 2018 | 602 | 0.52 | Why? |
| Bacterial Infections | 2 | 2018 | 2229 | 0.52 | Why? |
| Pyridines | 2 | 2020 | 680 | 0.52 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.51 | Why? |
| Cytomegalovirus | 5 | 2018 | 600 | 0.50 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 1165 | 0.48 | Why? |
| Intestines | 1 | 2018 | 817 | 0.47 | Why? |
| Herpes Zoster | 1 | 2017 | 331 | 0.47 | Why? |
| Iron | 1 | 2018 | 619 | 0.46 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.46 | Why? |
| Vancomycin | 4 | 2019 | 328 | 0.45 | Why? |
| Environment | 1 | 2017 | 769 | 0.43 | Why? |
| Immunoglobulins, Intravenous | 2 | 2021 | 2705 | 0.40 | Why? |
| Postoperative Complications | 5 | 2020 | 5861 | 0.39 | Why? |
| Immunocompromised Host | 5 | 2021 | 5150 | 0.37 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.36 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.35 | Why? |
| Immunologic Factors | 3 | 2020 | 4206 | 0.35 | Why? |
| Anti-Bacterial Agents | 7 | 2020 | 10083 | 0.35 | Why? |
| Transplants | 3 | 2018 | 136 | 0.35 | Why? |
| Quality of Health Care | 1 | 2018 | 1948 | 0.32 | Why? |
| Graft Rejection | 5 | 2021 | 1766 | 0.31 | Why? |
| Vitamin D | 2 | 2019 | 2904 | 0.31 | Why? |
| Disease Susceptibility | 2 | 2018 | 4002 | 0.31 | Why? |
| Spain | 9 | 2021 | 15545 | 0.30 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.30 | Why? |
| Immunosuppressive Agents | 7 | 2021 | 6331 | 0.30 | Why? |
| Vitamin D Deficiency | 1 | 2018 | 1782 | 0.28 | Why? |
| Biological Products | 1 | 2018 | 2331 | 0.26 | Why? |
| Blood Culture | 3 | 2018 | 308 | 0.23 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.23 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.21 | Why? |
| Middle Aged | 30 | 2021 | 270681 | 0.21 | Why? |
| Aged | 26 | 2021 | 215776 | 0.20 | Why? |
| Coagulase | 1 | 2019 | 44 | 0.20 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.19 | Why? |
| Antiviral Agents | 5 | 2020 | 41703 | 0.19 | Why? |
| Bacteriuria | 1 | 2018 | 31 | 0.19 | Why? |
| Methicillin | 1 | 2018 | 73 | 0.19 | Why? |
| Incidence | 5 | 2018 | 25622 | 0.19 | Why? |
| Salvage Therapy | 1 | 2021 | 417 | 0.18 | Why? |
| Tissue Donors | 2 | 2018 | 1679 | 0.18 | Why? |
| Male | 29 | 2021 | 367725 | 0.18 | Why? |
| Administration, Inhalation | 2 | 2021 | 1647 | 0.17 | Why? |
| Risk Factors | 12 | 2021 | 71621 | 0.17 | Why? |
| Prospective Studies | 14 | 2021 | 43301 | 0.17 | Why? |
| Adult | 22 | 2021 | 244371 | 0.17 | Why? |
| Wisconsin | 1 | 2019 | 607 | 0.17 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2017 | 93 | 0.17 | Why? |
| Female | 29 | 2021 | 380317 | 0.17 | Why? |
| Monitoring, Immunologic | 1 | 2018 | 153 | 0.17 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 711 | 0.16 | Why? |
| Central Venous Catheters | 1 | 2019 | 188 | 0.16 | Why? |
| Treatment Adherence and Compliance | 1 | 2018 | 194 | 0.16 | Why? |
| Candidiasis, Invasive | 1 | 2018 | 107 | 0.16 | Why? |
| Premedication | 1 | 2016 | 40 | 0.16 | Why? |
| Humans | 43 | 2021 | 930598 | 0.16 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.16 | Why? |
| Respiratory Rate | 1 | 2020 | 691 | 0.15 | Why? |
| Postoperative Period | 1 | 2018 | 651 | 0.15 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.15 | Why? |
| Allografts | 1 | 2019 | 761 | 0.15 | Why? |
| Bronchodilator Agents | 1 | 2021 | 444 | 0.15 | Why? |
| Models, Immunological | 1 | 2021 | 727 | 0.15 | Why? |
| L-Lactate Dehydrogenase | 2 | 2020 | 1995 | 0.15 | Why? |
| Population Groups | 1 | 2017 | 212 | 0.14 | Why? |
| Follow-Up Studies | 5 | 2021 | 17020 | 0.14 | Why? |
| Body Temperature | 1 | 2020 | 875 | 0.14 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.14 | Why? |
| Graft Survival | 1 | 2017 | 587 | 0.14 | Why? |
| Travel Medicine | 1 | 2018 | 335 | 0.14 | Why? |
| Interferon-beta | 1 | 2020 | 979 | 0.13 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.13 | Why? |
| Candidiasis | 1 | 2018 | 334 | 0.13 | Why? |
| Endemic Diseases | 1 | 2018 | 480 | 0.13 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2020 | 634 | 0.13 | Why? |
| Echinocandins | 1 | 2014 | 139 | 0.13 | Why? |
| Risk Assessment | 6 | 2020 | 25439 | 0.12 | Why? |
| Chemoprevention | 1 | 2017 | 585 | 0.12 | Why? |
| Regression Analysis | 2 | 2017 | 2484 | 0.12 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.12 | Why? |
| Ferritins | 2 | 2020 | 2055 | 0.12 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Drug Resistance, Multiple, Bacterial | 2 | 2018 | 1115 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.12 | Why? |
| Endocarditis | 1 | 2017 | 368 | 0.11 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 7868 | 0.11 | Why? |
| Clostridium Infections | 1 | 2019 | 595 | 0.11 | Why? |
| Spatial Analysis | 1 | 2017 | 878 | 0.11 | Why? |
| Biomarkers | 4 | 2020 | 23361 | 0.11 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.11 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.11 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.11 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.11 | Why? |
| Donor Selection | 1 | 2018 | 804 | 0.11 | Why? |
| Heart Rate | 1 | 2020 | 1527 | 0.11 | Why? |
| Geography | 1 | 2017 | 1801 | 0.11 | Why? |
| Time Factors | 3 | 2019 | 31397 | 0.11 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.11 | Why? |
| Drug Resistance, Viral | 1 | 2017 | 1083 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2020 | 5440 | 0.10 | Why? |
| Methylprednisolone | 1 | 2021 | 2107 | 0.10 | Why? |
| Survival Analysis | 2 | 2020 | 7592 | 0.10 | Why? |
| Mycoses | 1 | 2016 | 589 | 0.10 | Why? |
| Cost-Benefit Analysis | 1 | 2019 | 2259 | 0.09 | Why? |
| Aged, 80 and over | 10 | 2021 | 88759 | 0.09 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.09 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.09 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2017 | 2093 | 0.08 | Why? |
| Hematologic Neoplasms | 1 | 2020 | 2105 | 0.08 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.08 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.08 | Why? |
| Liver | 2 | 2018 | 4007 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Lung Transplantation | 1 | 2017 | 1554 | 0.08 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.08 | Why? |
| beta-Glucans | 2 | 2018 | 176 | 0.08 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.07 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.07 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.07 | Why? |
| Liver Transplantation | 1 | 2020 | 2864 | 0.07 | Why? |
| Kidney Failure, Chronic | 1 | 2020 | 3222 | 0.07 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Endocarditis, Bacterial | 1 | 2009 | 344 | 0.07 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2018 | 4927 | 0.06 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.06 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.06 | Why? |
| Latin America | 2 | 2018 | 1721 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| Hyperoxaluria, Primary | 1 | 2020 | 15 | 0.06 | Why? |
| Microbial Sensitivity Tests | 3 | 2017 | 2886 | 0.05 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.05 | Why? |
| Amphotericin B | 1 | 2020 | 256 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2018 | 7218 | 0.05 | Why? |
| Deprescriptions | 1 | 2020 | 294 | 0.05 | Why? |
| Ceftriaxone | 1 | 2020 | 365 | 0.05 | Why? |
| Mycophenolic Acid | 1 | 2020 | 383 | 0.05 | Why? |
| Antibodies, Fungal | 1 | 2018 | 49 | 0.05 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.04 | Why? |
| Disk Diffusion Antimicrobial Tests | 1 | 2017 | 36 | 0.04 | Why? |
| Europe | 3 | 2021 | 12702 | 0.04 | Why? |
| Tacrolimus | 1 | 2020 | 435 | 0.04 | Why? |
| DNA, Viral | 2 | 2017 | 2521 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Sequence Analysis, DNA | 2 | 2017 | 2830 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Prednisone | 1 | 2020 | 652 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2019 | 511 | 0.04 | Why? |
| Models, Economic | 1 | 2019 | 316 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2018 | 9044 | 0.04 | Why? |
| Predictive Value of Tests | 2 | 2021 | 9537 | 0.04 | Why? |
| Lymphoma | 1 | 2020 | 522 | 0.04 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.04 | Why? |
| Early Diagnosis | 2 | 2018 | 2443 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.03 | Why? |
| Young Adult | 3 | 2019 | 93724 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 877 | 0.03 | Why? |
| Drug Resistance, Fungal | 1 | 2014 | 191 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| National Health Programs | 1 | 2019 | 807 | 0.03 | Why? |
| Multiple Myeloma | 1 | 2020 | 1064 | 0.03 | Why? |
| Health Care Costs | 1 | 2019 | 1007 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 11367 | 0.02 | Why? |
| Child | 1 | 2019 | 70012 | 0.02 | Why? |
| Candida | 1 | 2014 | 425 | 0.02 | Why? |
| Methicillin Resistance | 1 | 2009 | 77 | 0.02 | Why? |
| Animals | 1 | 2018 | 78931 | 0.02 | Why? |
| Disease Outbreaks | 1 | 2017 | 27595 | 0.02 | Why? |
| Adolescent | 1 | 2019 | 86841 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Lymphocytes | 1 | 2020 | 3056 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2021 | 7268 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.02 | Why? |
| Catheterization | 1 | 2009 | 264 | 0.02 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Propensity Score | 1 | 2014 | 2690 | 0.02 | Why? |
| Prosthesis-Related Infections | 1 | 2009 | 302 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Catheterization, Central Venous | 1 | 2009 | 458 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Renal Dialysis | 1 | 2020 | 4358 | 0.02 | Why? |
| Heart Valve Prosthesis | 1 | 2009 | 533 | 0.02 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2009 | 552 | 0.01 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Equipment Contamination | 1 | 2009 | 1308 | 0.01 | Why? |
| Algorithms | 1 | 2016 | 7346 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Population Surveillance | 1 | 2014 | 4967 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.01 | Why? |
| Infant | 1 | 2014 | 30274 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2009 | 7330 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| Prevalence | 1 | 2009 | 25773 | 0.00 | Why? |
| Antibodies, Viral | 1 | 2018 | 51949 | 0.00 | Why? |